摘要
目的运用药物经济学原理,比较3种抗菌药物治疗肝硬化并自发性细菌性腹膜炎(SBP)的成本-效果分析。方法回顾性调查医院2009年8月-2010年8月应用3种抗菌药物治疗肝硬化并自发性细菌性腹膜炎的62例临床病历(A组为哌拉西林/他唑巴坦组;B组为头孢哌酮/他唑巴坦组;C组为氨曲南组),分析其药物利用及成本消耗情况。结果 3组临床的有效率分别为95.24%、85.71%、85.00%,临床效果分别为:85.24%、76.66%、75.50%;从成本效果分析,3组分别为:15.17%、28.81%、26.47%;从敏感度分析,3组分别为:12.73%、27.58%、25.76%;以上疗效-成本分析表明,哌拉西林/他唑巴坦(A组)具有较好的疗效成本比。结论哌拉西林/他唑巴坦对肝硬化并自发性细菌性腹膜炎临床疗效可靠,具有较好的疗效成本比,安全性高;可作为经验性治疗SBP的首选药物。
OBJECTIVE To compare cost-effectiveness to three antibiotics in treating cirrhosis combining with spontaneous bacterial peritonitis by using principles of economics.METHODS A retrospective survey was conducted for the clinical records of 62 cases with liver cirrhosis and spontaneous bacterial peritonitis treated by 3 kinds of antibiotics（A group of piperacillin/tazobactam group;B group cefoperazone/tazobactam group;C group aztreonam group） during Aug 2009-Aug 20010,the cost of their drug use and consumption were analyzed.RESULTS The clinical effective rates of the 3 groups were 95.24%,85.71% and 85.00% respectively,and the clinical effects were：85.24%,76.66% and 75.50%;cost-effectiveness analysis indicated that the three groups were：15.17%,28.81% and 26.47%;the sensitivity analysis showed that the three groups were：12.73%,27.58% and 25.76%;The efficacy-cost analysis showed that piperacillin/tazobactam（A group） had a good effect on the cost ratio.CONCLUSION Piperacillin/tazobactam in treating against cirrhosis and spontaneous bacterial peritonitis has a reliable clinical efficacy and cost effeotive.It can be used as preferred choice of drug for empirical treatment of SBP.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2011年第6期1211-1213,共3页
Chinese Journal of Nosocomiology
